References
1. Amer, S. , 2007. Gonadotrophin induction of ovulation. Obstet. Gynaecol. Reprod. Med. 205–210.
2. Amirikia H, Savoy-Moore RT, Sundareson AS, Moghissi KS. The effects of long-term androgen treatment on the ovary. Fertil Steril 1986;45:202–8.
3. Bailey CJ. Metformin revisited: its actions and indications for use. Diabet Med 1988;5:315–20.
4. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21:2845–9.
5. Barad D, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005;84:756.
6. Biljan MM, Buckett WM, Dean N, Phillips SJ, Tan SL. The outcome of IVF-embryo transfer treatment in patients who develop three follicles or less. Hum Reprod 2000;15:2140–2144.
7. Burger HG. Androgen production in women. Fertil Steril. 2002;77(Suppl 4):S3–5.
8. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 1998;70:107–10.
9. CofflerMS, Patel K, Dahan MH, Yoo RY,Malcom PJ, Chang RJ. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003;88:5624–31.
10. E. Y. Adashi, C. E. Resnick, A. J. D’Ercole, M. E. Svoboda, and J. J. Van Wyk, “Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function.,” Endocrine Reviews, vol. 6, no. 3, pp. 400–420, 1985.
11. Falbo A, Orio F, Venturella R, Rania E, Materazzo C, Tolino A, et al. Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis. J Ovarian Res 2009;31:2–5.
12. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008;14:367–78.
13. Fried G, Remaeus K, Harlin J, Krog E, Csemiczky G, Aanesen A, et al. Inhibin B predicts oocyte number and the ratio IGF-I/IGFBP-1 may indicate oocyte quality during ovarian hyperstimulation for in vitro fertilization. J Assist Reprod Genet. 2003;20 (5) :167–76.
14. Gleicher, N., Barad, D.H. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 2011;9, 67.
15. Gleicher, N., Weghofer, A., Barad, D.H., 2011. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod. Biol. Endocrinol. 9, 116.
16. Gleicher, N., Kim, A., Weghofer, A., Kushnir, V.A., Shohat-Tal, A., Lazzaroni, E., Lee, H.J., Barad, D.H., 2013. Hypoandrogenism in association with diminished functional ovarian reserve. Hum. Reprod. 28, 1084–1091.
17. Harper AJ, Buster JE, Casson PR. Changes in adrenocortical function with aging and therapeutic implications. Semin Reprod Endocrinol 1999;17:327–38.
18. Hillier SG, Whitelaw PF, Smyth CD. Follicular estrogen synthesis: the ‘2-cell, two-gonadotrophin’ model revisited. Mol Cell Endocrinol 1994;100:5–4.
19. Lin LT, Wang PH, Wen ZH, Li CJ, Chen SN, Tsai EM, et al. The application of Dehydroepiandrosterone on improving mitochondrial function and reducing apoptosis of cumulus cells in poor ovarian responders. Int J Med Sci. 2017;14(6):585–94.
20. Magamage MPS, Zengyo M, Moniruzzaman M, Miyano T. Testosterone induces activation of porcine primordial follicles in vitro. Reprod Med Biol. 2011;10(1):21–30.
21. McGee, E.A., Hsueh, A.J., 2000. Initial and cyclic recruitment of ovarian follicles. Endocr. Rev. 21, 200–214.
22. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–1880.
23.Orvieto R, Meltcer S, Nahum R, Rabinson J, Anteby EY, Ashkenazi J. The influence of body mass index on in vitro fertilization outcome. Int J Gynaecol Obstet 2009; 104:53–55.
24. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1–50.
25. Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod 2010;25:1005–13.
26. Sen A, Prizant H, Light A, Biswas A, Hayes E, Lee HJ, et al. Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc Natl Acad Sci U S A. 2014;111(8):3008–13.
27. Smith P, Steckler TL, Veiga-Lopez A, Padmanabhan V. Developmental programming: differential effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, depletion of follicular reserve, and ovarian morphology in sheep. Biol Reprod. 2009;80(4):726–36.
28. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck DJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43: 647–54.
29. X.-C. Jia, J. Kalmijn, and A. J. W. Hsueh, “Growth hormone enhances follicle
Stimulating hormone induced differentiation of cultured rat granulosa cells,” Endocrinology, vol. 118, no. 4, pp. 1401–1409, 1986.